{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-23-000059","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.767642+00:00","generated_at":"2026-06-08T05:59:50.238208+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novavax Q3 revenue $187M (down 75% YoY); FY23 revenue guidance lowered to $900M-$1.1B","bullets":["Q3 2023 total revenue $187M vs $735M YoY; net loss $131M improved from $169M loss YoY.","FY2023 total revenue guidance cut to $900M-$1.1B from prior $1.3B-$1.5B; expects additional $300M in Q1 2024.","Additional cost reduction of >$300M in 2024 targeting R&D/SG&A <$750M and >$100M supply network savings.","Received FDA EUA for updated COVID-19 vaccine Oct 2023; available at ~14,000 U.S. pharmacy locations.","WHO recommended R21/Matrix-M malaria vaccine; initial Matrix-M sales recognized in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-23-000059","json":"https://secwatch.observer/filing/0001000694-23-000059.json","markdown":"https://secwatch.observer/filing/0001000694-23-000059.md","text":"https://secwatch.observer/filing/0001000694-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000059/0001000694-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000059/nvax-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:59:50.238208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0af28d5ed8c43441f80c4ae3cea46677b0dcc833","claim":"NOVAVAX INC reported the third quarter ended September 30, 2023 results: revenue $187 million, net income Net loss of $131 million.","evidence_excerpt":"received recommendation from the World Health Organization; launch expected in 2024 2 Third Quarter 2023 Financial Results • Total revenue for the third quarter of 2023 was $187 million, compared to $735 million in the same period in 2022. Third quarter 2023 grant revenue of $165 million benefited from milestone achievements related to U.S. market preparedness","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000059/0001000694-23-000059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$187 million"},{"label":"Net income","value":"Net loss of $131 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}